| Gene symbol | CD33 | Synonyms | CD33rSiglec, SIGLEC-3, SIGLEC3, p67 | Type of gene | protein-coding | |
| Chromosome | 19 | Map location | 19q13.41 | dbXrefs | Entrez:945 MIM:159590 HGNC:HGNC:1659 Ensembl:ENSG00000105383 AllianceGenome:HGNC:1659 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | CD33 molecule | |||||
| GTO ID | GTC3539 |
| Trial ID | NCT05984199 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | CD33 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | VCAR33 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation |
| Year | 2023 |
| Country | United States |
| Company sponsor | Vor Biopharma |
| Other ID(s) | VBP301 |
| Cohort 1 | |||||||||
|
|||||||||